Publications by authors named "Fausto Barbieri"

Claim this Profile
T
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
Giulia Mazzaschi, Fabiana Perrone, Roberta Minari, Michela Verzè, Cinzia Azzoni, Fausto Barbieri

Clin Lung Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
Paolo Bironzo, Laura Melocchi, Valentina Monica, Dario Trebeschi, Fausto Barbieri

Pathologica· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres.
Paolo Cameli, Paola Faverio, Katia Ferrari, Viola Bonti, Stefania Marsili, Fausto Barbieri

Life (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report.
Lucia Trudu, Giorgia Guaitoli, Federica Bertolini, Michela Maur, Chiara Santini, Fausto Barbieri

Immunotherapy· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.
Fabiana Perrone, Giulia Mazzaschi, Roberta Minari, Michela Verzè, Cinzia Azzoni, Fausto Barbieri

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Elisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, Ferdinando Riccardi, Andrea Bonetti, Fausto Barbieri

Future Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy.
Cinzia Baldessari, Annarita Pecchi, Raffaella Marcheselli, Giorgia Guaitoli, Riccardo Bonacini, Fausto Barbieri

Immunotherapy· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deepening the Knowledge of Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Fausto Barbieri

Int J Mol Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Francesco Gelsomino, Marcello Tiseo, Fausto Barbieri, Ferdinando Riccardi, Luigi Cavanna

Br J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, Sergio Bracarda, Massimo Di Maio, Fausto Barbieri

Eur J Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy.
Cinzia Baldessari, Giorgia Guaitoli, Filippo Valoriani, Riccardo Bonacini, Raffaella Marcheselli, Fausto Barbieri

Clin Nutr ESPEN· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Alessio Cortellini, Massimo Di Maio, Olga Nigro, Alessandro Leonetti, Diego L Cortinovis, Fausto Barbieri

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report.
Giorgia Guaitoli, Fausto Barbieri, Monica Barbolini, Eleonora Molinaro, Katia Di Emidio

Immunotherapy· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, Federico Cappuzzo, Joachim G J V Aerts, Fausto Barbieri

Cancer Immunol Immunother· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Fausto Barbieri

Ther Adv Med Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE).
Alessandro Marchioni, Dario Andrisani, Roberto Tonelli, Roberto Piro, Alessandro Andreani, Fausto Barbieri

Lung Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, Emilio Bria, Giuseppe L Banna, Fausto Barbieri

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Francesco Gelsomino, Marcello Tiseo, Fausto Barbieri, Ferdinando Riccardi, Luigi Cavanna

Br J Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, Francesco Passiglia, Francesca Mazzoni

Eur J Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report.
Annapaola Mariniello, Eleonora Ghisoni, Luisella Righi, Annamaria Catino, Rita Chiari, Fausto Barbieri

In Vivo· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Maria Lucia Reale, Rita Chiari, Marcello Tiseo, Fabiana Vitiello, Fausto Barbieri

Lung Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating cancer with immunotherapy in HIV-positive patients: A challenging reality.
Giorgia Guaitoli, Cinzia Baldessari, Michela Maur, Cristina Mussini, Marianna Meschiari, Fausto Barbieri

Crit Rev Oncol Hematol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'Incà, Claudio Dazzi, Fausto Barbieri

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma.
Lorena Losi, Federica Bertolini, Giorgia Guaitoli, Luca Fabbiani, Federico Banchelli, Fausto Barbieri

Int J Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are we ready to describe response or progression to immunotherapy in lung cancer?
Giorgia Guaitoli, Cinzia Baldessari, Federica Bertolini, Chiara Tomasello, Stefano Cascinu, Fausto Barbieri

Crit Rev Oncol Hematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis